Drug Resistance in Pneumonia (DRIP) Score

The DRIP score is a clinical tool that predicts the likelihood of drug‑resistant pathogens in community‑onset pneumonia to guide empiric antibiotic selection 1.

Antibiotic use within 60 days?
No0Yes+2
Long-term care resident (not assisted living or group home)?
No0Yes+2
Tube Feeding (nasogastric, nasojejunal or percutaneous gastrostomy)?
No0Yes+2
Prior drug-resistant pneumonia within 1 year?
No0Yes+2
Prior hospitalization within 60 days?
No0Yes+1
Chronic pulmonary disease?
No0Yes+1
Poor functional status (Karnofsky Performance Status less than 70 or non-ambulatory status)?
No0Yes+1
H2 blocker or PPI within 14 days?
No0Yes+1
Active wound care at time of admission?
No0Yes+1
MRSA colonization within 1 year?
No0Yes+1

Indications for Use

Used for adults with community-onset pneumonia when estimating likelihood of drug‑resistant pathogens to guide empiric need for anti‑MRSA or antipseudomonal therapy. A score ≥4 identifies higher risk, helping avoid unnecessary broad‑spectrum use and reducing overtreatment by ~46% compared with HCAP criteria 1 [Level II evidence]. Validation shows AUROC ≈0.88 with NPV ≈0.90, supporting its role as a stewardship tool 1 [Level II evidence].

Insights & Cautions

Stratify risk using major predictors such as recent hospitalization or antibiotics and minor factors like chronic illness or tube feeding; higher scores identify patients more likely to harbor resistant pathogens. The score reduces unnecessary broad‑spectrum antibiotics but remains imperfect, with moderate discrimination (AUROC 0.88 in derivation 1 [Level II evidence]) and lower performance in external datasets (C‑statistic 0.63 2 [Level II evidence]). Use only alongside local epidemiology and clinical judgment.